THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS

• US 20160168164A1
• Filed: 07/29/2014
• Published: 06/16/2016
• Est. Priority Date: 07/30/2013
• Status: Active Grant

• Current Assignee: Janssen Sciences Ireland Unlimited Company (Johnson & Johnson)
• Original Assignee: Janssen Sciences Ireland UC (Johnson & Johnson)
• Inventors: MC GOWAN, David Craig, RABOISSON, Pierre Jean-Marie Bernard
• Granted Patent: US 9,556,199 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 495/04 Ortho-condensed systems

Abstract

This invention relates to thieno[3,2-d]pyrimidines derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

Claims

1. A compound of formula (I)

2. A compound according to claim 1 wherein R₁ and R₂ are both hydrogen and wherein R₃ is C_1-8 alkyl substituted by hydroxyl.

3. A compound according to claim 2 having the structure

4. A pharmaceutical composition comprising a compound according to claim 1 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

6. A method of treating a disorder in which the modulation of TLR 7 and/or TLR 8 is involved, comprising the administration of a therapeutically effective amount of at least one compound of claim 1.

7. The method of claim 6, wherein the disorder is a viral infection.

8. A compound according to claim 1 having the structure

9. A compound according to claim 1, wherein R₂ is H, CH₃ or C(CH₃)₃.

10. A compound according to claim 1, wherein R₃ is selected from the group consisting of

11. A compound according to claim 1 wherein R₁ is H and R₂ is CH₃.

12. A compound according to claim 1 wherein R₁ is CH₃ and R₂ is H.

13. A compound according to claim 1 wherein R₁ and R₂ are H.

14. A compound according to claim 1, wherein R₃ is selected from the group consisting of

15. A compound according to claim 1, wherein R₃ is

21. A method of preparing a compound of claim 1.

5. (canceled)

16. A compound selected from the group consisting of

17. A compound as claimed in claim 16, selected from the group consisting of

18. A pharmaceutical composition comprising a compound according to claim 16 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

19. A method of treating a disorder in which the modulation of TLR 7 and/or TLR 8 is involved, comprising the administration of a therapeutically effective amount of at least one compound as claimed in claim 16.

20. The method of claim 19, wherein the disorder is a viral infection.